• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

小高密度脂蛋白中载脂蛋白A-I淀粉样变变体的结构动力学增强了它们介导胆固醇流出的能力。

Structure dynamics of ApoA-I amyloidogenic variants in small HDL increase their ability to mediate cholesterol efflux.

作者信息

Nilsson Oktawia, Lindvall Mikaela, Obici Laura, Ekström Simon, Lagerstedt Jens O, Del Giudice Rita

机构信息

Department of Experimental Medical Science, Lund University, Lund, Sweden.

Amyloidosis Research & Treatment Centre, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.

出版信息

J Lipid Res. 2021;62:100004. doi: 10.1194/jlr.RA120000920. Epub 2020 Nov 24.

DOI:10.1194/jlr.RA120000920
PMID:33410751
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7890215/
Abstract

Apolipoprotein A-I (ApoA-I) of high density lipoproteins (HDLs) is essential for the transportation of cholesterol between peripheral tissues and the liver. However, specific mutations in ApoA-I of HDLs are responsible for a late-onset systemic amyloidosis, the pathological accumulation of protein fibrils in tissues and organs. Carriers of these mutations do not exhibit increased cardiovascular disease risk despite displaying reduced levels of ApoA-I/HDL cholesterol. To explain this paradox, we show that the HDL particle profiles of patients carrying either L75P or L174S ApoA-I amyloidogenic variants show a higher relative abundance of the 8.4-nm versus 9.6-nm particles and that serum from patients, as well as reconstituted 8.4- and 9.6-nm HDL particles (rHDL), possess increased capacity to catalyze cholesterol efflux from macrophages. Synchrotron radiation circular dichroism and hydrogen-deuterium exchange revealed that the variants in 8.4-nm rHDL have altered secondary structure composition and display a more flexible binding to lipids than their native counterpart. The reduced HDL cholesterol levels of patients carrying ApoA-I amyloidogenic variants are thus balanced by higher proportion of small, dense HDL particles, and better cholesterol efflux due to altered, region-specific protein structure dynamics.

摘要

高密度脂蛋白(HDL)中的载脂蛋白A-I(ApoA-I)对于外周组织与肝脏之间的胆固醇运输至关重要。然而,HDL的ApoA-I中的特定突变会导致迟发性全身性淀粉样变性,即蛋白质原纤维在组织和器官中的病理性积累。尽管携带这些突变的个体ApoA-I/HDL胆固醇水平降低,但他们并未表现出心血管疾病风险增加。为了解释这一矛盾现象,我们发现携带L75P或L174S ApoA-I淀粉样变性变体的患者的HDL颗粒谱显示,与9.6纳米颗粒相比,8.4纳米颗粒的相对丰度更高,并且患者的血清以及重组的8.4纳米和9.6纳米HDL颗粒(rHDL)具有增强的催化巨噬细胞胆固醇流出的能力。同步辐射圆二色性和氢-氘交换表明,8.4纳米rHDL中的变体具有改变的二级结构组成,并且与脂质的结合比其天然对应物更灵活。因此,携带ApoA-I淀粉样变性变体的患者HDL胆固醇水平的降低被较高比例的小而致密的HDL颗粒以及由于改变的、区域特异性蛋白质结构动力学导致的更好的胆固醇流出所平衡。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b538/7890215/822389967126/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b538/7890215/776504ea5a05/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b538/7890215/30a2e2e83d15/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b538/7890215/9fa8156bf7a9/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b538/7890215/28594c4a93b2/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b538/7890215/9a102b3793cf/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b538/7890215/822389967126/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b538/7890215/776504ea5a05/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b538/7890215/30a2e2e83d15/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b538/7890215/9fa8156bf7a9/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b538/7890215/28594c4a93b2/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b538/7890215/9a102b3793cf/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b538/7890215/822389967126/gr6.jpg

相似文献

1
Structure dynamics of ApoA-I amyloidogenic variants in small HDL increase their ability to mediate cholesterol efflux.小高密度脂蛋白中载脂蛋白A-I淀粉样变变体的结构动力学增强了它们介导胆固醇流出的能力。
J Lipid Res. 2021;62:100004. doi: 10.1194/jlr.RA120000920. Epub 2020 Nov 24.
2
Lipid exchange of apolipoprotein A-I amyloidogenic variants in reconstituted high-density lipoprotein with artificial membranes.载脂蛋白 A-I 淀粉样变体在人工膜重建的高密度脂蛋白中的脂质交换。
Protein Sci. 2024 May;33(5):e4987. doi: 10.1002/pro.4987.
3
Structural determinants in ApoA-I amyloidogenic variants explain improved cholesterol metabolism despite low HDL levels.载脂蛋白 A-I 淀粉样变变体中的结构决定因素解释了尽管 HDL 水平低但胆固醇代谢仍得到改善的原因。
Biochim Biophys Acta Mol Basis Dis. 2017 Dec;1863(12):3038-3048. doi: 10.1016/j.bbadis.2017.09.001. Epub 2017 Sep 6.
4
Structure-function relationships in reconstituted HDL: Focus on antioxidative activity and cholesterol efflux capacity.富含高密度脂蛋白的结构与功能关系:重点关注抗氧化活性和胆固醇外排能力。
Biochim Biophys Acta Mol Cell Biol Lipids. 2017 Sep;1862(9):890-900. doi: 10.1016/j.bbalip.2017.05.010. Epub 2017 May 18.
5
Structure-function analysis of naturally occurring apolipoprotein A-I L144R, A164S and L178P mutants provides insight on their role on HDL levels and cardiovascular risk.对天然载脂蛋白 A-I L144R、A164S 和 L178P 突变体的结构-功能分析为其在 HDL 水平和心血管风险中的作用提供了深入了解。
Cell Mol Life Sci. 2021 Feb;78(4):1523-1544. doi: 10.1007/s00018-020-03583-y. Epub 2020 Jul 14.
6
The effect of high density lipoprotein phospholipid acyl chain composition on the efflux of cellular free cholesterol.高密度脂蛋白磷脂酰链组成对细胞游离胆固醇流出的影响。
J Biol Chem. 1995 Mar 17;270(11):5882-90. doi: 10.1074/jbc.270.11.5882.
7
Interaction of reconstituted high density lipoprotein discs containing human apolipoprotein A-I (ApoA-I) variants with murine adipocytes and macrophages. Evidence for reduced cholesterol efflux promotion by apoA-I(Pro165-->Arg).含人载脂蛋白A-I(ApoA-I)变体的重组高密度脂蛋白圆盘与小鼠脂肪细胞和巨噬细胞的相互作用。载脂蛋白A-I(Pro165→Arg)促进胆固醇外流减少的证据。
J Biol Chem. 1993 Feb 5;268(4):2616-22.
8
Cell cholesterol efflux to reconstituted high-density lipoproteins containing the apolipoprotein A-IMilano dimer.细胞胆固醇向含有载脂蛋白A-米兰二聚体的重组高密度脂蛋白的流出。
Biochemistry. 1999 Dec 7;38(49):16307-14. doi: 10.1021/bi991246n.
9
Effect of the amyloidogenic L75P apolipoprotein A-I variant on HDL subpopulations.载脂蛋白 A-I L75P 淀粉样变体对 HDL 亚群的影响。
Clin Chim Acta. 2011 Jun 11;412(13-14):1262-5. doi: 10.1016/j.cca.2011.03.027. Epub 2011 Mar 31.
10
Apolipoprotein A-I structural modification and the functionality of reconstituted high density lipoprotein particles in cellular cholesterol efflux.载脂蛋白A-I的结构修饰与重组高密度脂蛋白颗粒在细胞胆固醇流出中的功能
J Biol Chem. 1996 Sep 27;271(39):23792-8. doi: 10.1074/jbc.271.39.23792.

引用本文的文献

1
Dissecting the properties of circulating IgG against streptococcal pathogens through a combined systems antigenomics-serology workflow.通过系统抗原组学-血清学联合工作流程剖析循环免疫球蛋白G针对链球菌病原体的特性。
Nat Commun. 2025 Feb 24;16(1):1942. doi: 10.1038/s41467-025-57170-5.
2
Anti-inflammatory mechanism of Apolipoprotein A-I.载脂蛋白 A-I 的抗炎机制。
Front Immunol. 2024 Jul 8;15:1417270. doi: 10.3389/fimmu.2024.1417270. eCollection 2024.
3
Lipid exchange of apolipoprotein A-I amyloidogenic variants in reconstituted high-density lipoprotein with artificial membranes.
载脂蛋白 A-I 淀粉样变体在人工膜重建的高密度脂蛋白中的脂质交换。
Protein Sci. 2024 May;33(5):e4987. doi: 10.1002/pro.4987.
4
The Apparent Organ-Specificity of Amyloidogenic ApoA-I Variants Is Linked to Tissue-Specific Extracellular Matrix Components.淀粉样变性载脂蛋白 A-I 变体的明显器官特异性与组织特异性细胞外基质成分有关。
Int J Mol Sci. 2022 Dec 24;24(1):318. doi: 10.3390/ijms24010318.
5
Apolipoprotein A1 is associated with pulmonary vascular resistance and adverse clinical outcomes in patients with pulmonary hypertension secondary to heart failure.载脂蛋白A1与心力衰竭继发肺动脉高压患者的肺血管阻力及不良临床结局相关。
Pulm Circ. 2022 Jul 1;12(3):e12096. doi: 10.1002/pul2.12096. eCollection 2022 Jul.
6
Autophagy Alteration in ApoA-I Related Systemic Amyloidosis.载脂蛋白 A-I 相关系统性淀粉样变性中的自噬改变。
Int J Mol Sci. 2022 Mar 23;23(7):3498. doi: 10.3390/ijms23073498.
7
Advances in Hydrogen/Deuterium Exchange Mass Spectrometry and the Pursuit of Challenging Biological Systems.氢/氘交换质谱技术的进展及对挑战性生物系统的探索。
Chem Rev. 2022 Apr 27;122(8):7562-7623. doi: 10.1021/acs.chemrev.1c00279. Epub 2021 Sep 7.
8
High Density Lipoprotein Cholesterol Efflux Capacity and Atherosclerosis in Cardiovascular Disease: Pathophysiological Aspects and Pharmacological Perspectives.高密度脂蛋白胆固醇外排能力与心血管疾病中的动脉粥样硬化:病理生理方面和药物治疗观点。
Cells. 2021 Mar 5;10(3):574. doi: 10.3390/cells10030574.